Literature DB >> 21605035

AICD nuclear signaling and its possible contribution to Alzheimer's disease.

Uwe Konietzko1.   

Abstract

Altered proteolytic processing of the β-amyloid precursor protein (APP) is a central event in familial and sporadic Alzheimer's disease (AD). In a process termed regulated intramembrane proteolysis (RIP), APP first undergoes ectodomain shedding executed either by α- secretases at the plasma membrane or by β-secretase in the endosomal compartment. The remaining membrane-anchored stubs are cleaved within the membrane plane by the γ-secretase complex, releasing the APP intracellular domain (AICD) into the cytosol and leading to the generation of the Aβ peptide in the amyloidogenic pathway that is initiated by β-secretase. The Aβ peptides aggregate to form soluble oligomers and finally deposit into amyloid plaques that are a hallmark of AD. Recent evidence indicates a role for Aβ oligomers in regulating synaptic plasticity with excess amounts of oligomers disrupting synaptic function. The amyloid cascade hypothesis of AD is centered on the Aβ peptide, the APP fragment that has been most intensely studied, while other cleavage products have been largely neglected. The secreted ectodomain generated after α-cleavage in the non-amyloidogenic pathway has neurotrophic and neuroproliferative activities, thus opposing the neurotoxicity observed with high concentrations of Aβ. Further, in analogy to many other membrane proteins that are subject to RIP, AICD can translocate to the nucleus to regulate transcription. Many RIP substrates are localized to the synapse and thus could convey a direct signal from the synapse to the nucleus upon cleavage. Evidence indicates that only the amyloidogenic pathway generates AICD capable of nuclear signaling, due to the subcellular compartmentalization of APP processing. In aging and sporadic AD there is an increase in β-secretase levels and activity generating more Aβ peptides and concomitantly leading to an increase in AICD nuclear signaling. In this review, I summarize the current knowledge on AICD nuclear signaling and propose mechanisms to explain how this physiological function of APP might impact the pathology seen in AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21605035     DOI: 10.2174/156720512799361673

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  17 in total

Review 1.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 2.  Cortical odor processing in health and disease.

Authors:  Donald A Wilson; Wenjin Xu; Benjamin Sadrian; Emmanuelle Courtiol; Yaniv Cohen; Dylan C Barnes
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

Review 3.  Not just amyloid: physiological functions of the amyloid precursor protein family.

Authors:  Ulrike C Müller; Thomas Deller; Martin Korte
Journal:  Nat Rev Neurosci       Date:  2017-03-31       Impact factor: 34.870

4.  Amyloid precursor protein (APP) regulates synaptic structure and function.

Authors:  Sheue-Houy Tyan; Ann Yu-Jung Shih; Jessica J Walsh; Hiroko Maruyama; Floyd Sarsoza; Lawrence Ku; Simone Eggert; Patrick R Hof; Edward H Koo; Dara L Dickstein
Journal:  Mol Cell Neurosci       Date:  2012-08-03       Impact factor: 4.314

Review 5.  Dynamic self-guiding analysis of Alzheimer's disease.

Authors:  Alexei Kurakin; Dale E Bredesen
Journal:  Oncotarget       Date:  2015-06-10

6.  Pharmacological targeting of the β-amyloid precursor protein intracellular domain.

Authors:  Caterina Branca; Ilenia Sarnico; Roberta Ruotolo; Annamaria Lanzillotta; Arturo Roberto Viscomi; Marina Benarese; Vanessa Porrini; Luca Lorenzini; Laura Calzà; Bruno Pietro Imbimbo; Simone Ottonello; Marina Pizzi
Journal:  Sci Rep       Date:  2014-04-09       Impact factor: 4.379

Review 7.  Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Caroline Kerridge; Anthony J Turner
Journal:  Front Aging Neurosci       Date:  2014-09-17       Impact factor: 5.750

8.  The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus.

Authors:  Inger Lauritzen; Raphaëlle Pardossi-Piquard; Charlotte Bauer; Elizabeth Brigham; Jean-Daniel Abraham; Sébastien Ranaldi; Paul Fraser; Peter St-George-Hyslop; Ophelia Le Thuc; Vanessa Espin; Linda Chami; Julie Dunys; Frédéric Checler
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  APP intracellular domain-WAVE1 pathway reduces amyloid-β production.

Authors:  Ilaria Ceglia; Christiane Reitz; Jodi Gresack; Jung-Hyuck Ahn; Victor Bustos; Marina Bleck; Xiaozhu Zhang; Grant Martin; Sanford M Simon; Angus C Nairn; Paul Greengard; Yong Kim
Journal:  Nat Med       Date:  2015-08-17       Impact factor: 53.440

10.  Visualization and quantification of APP intracellular domain-mediated nuclear signaling by bimolecular fluorescence complementation.

Authors:  Florian Riese; Sonja Grinschgl; Manuel T Gersbacher; Natalie Russi; Christoph Hock; Roger M Nitsch; Uwe Konietzko
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.